期刊文献+

艾塞那肽对2型糖尿病患者胰岛素敏感性的影响 被引量:1

The effects of exenatide on insulin sensitivity in type 2 diabetics patients
原文传递
导出
摘要 目的 观察短期艾塞那肽治疗对2型糖尿病患者胰岛素敏感性的作用.方法 42例口服磺脲类药物治疗糖化血红蛋白不达标的2型糖尿病患者,按数字表法随机分为两组;艾塞那肽组20例,甘精胰岛素组22例,各组患者均给予糖尿病常规治疗,继续使用原用药物,同时艾塞那肽组使用艾塞那肽早晚餐前皮下注射,甘精胰岛素组给予甘精胰岛素每晚睡前注射1次,共治疗5个月.治疗前后采用高胰岛素-正葡萄糖钳夹术评价两组胰岛素敏感性,并测定相关代谢指标.结果 与治疗前比较,艾塞那肽组葡萄糖代谢率升高[(5.12±0.35)与(2.94±0.41)]mg· kg-1·min-1,P<0.05],稳态模型评估胰岛素抵抗指数(HOMA-IR)降低[4.51(1.32 ~6.12)与1.96(1.32 ~6.12),P<0.05],体质量指数下降较甘精胰岛素组显著(P<0.05);两组均无严重低血糖事件发生.结论 短期艾塞那肽治疗对2型糖尿病患者胰岛素敏感性有改善作用. Objective To investigate the effects of exenatide on insulin sensitivity in type 2 diabetics.Methods 42 diabetics of secondary failure of sulfonylurea were recruited in the study,and were distinguished to the exenatide group and the glargine group.Besides being treated with diabetic conventional and original treatments,the two groups were given respectively exenatide before breakfast and dinner,or glargine before sleeping by subcutaneous injection for five weeks.Insulin sensitivity of the two groups was elevated by euglycemic-hyperinsulinemic clamps before and after treatment.The metabolic indices were determined.Results Compared with baseline levels,after treatment the glucose metabolic rate was improved [(5.12 ± 0.35) vs (2.94 ± 0.41)] mg · kg-1 · min-1,P 〈 0.05],the BMI and HMOA-IR was reduced[4.51 (1.32 ~ 6.12) vs 1.96 (1.32 ~ 6.12)],in the exenatide groups,which were better than the glargine group (P 〈 0.05).Gastrointestinal adverse reactions,which were tolerable and decreased,were appeared in nearly 31.42% of subjects.There were no severe hypoglycemic events in both groups.Conclusion Short-term treatment with exenatide could improve the insulin sensitivity of type 2 diabetics.
出处 《中国基层医药》 CAS 2013年第19期2924-2926,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 糖尿病 2型 艾塞那肽 Diabetes mellitus, type 2 Exenatide
  • 相关文献

参考文献16

  • 1Hoist JJ,Gromada J. Role of inrcretin hormones in the regulation of insulin secretion in diabetic and nondianbetic humans. Am J Physiol Endecrinol Metab,2004,287(2) :E199-E206.
  • 2Deacon CF. Therapeutic strategies based on glueagons-like peptidel. Diabetes,2004,53 (9) :2181-2189.
  • 3Meier JJ ,Nauek MA. Is the din'finished ineretin effect in type 2diabetes just an epi-phenomenon of impaired beta-ceU function. Diabetes,2010, 59(5) :1117-1125.
  • 4Kolterman OD, Kim DD, Shen L, et al. Pharmacokinetics, pharmaeodynamics, and safety of exenatide in patients with type 2 diabe- tes mellitus. Am J Health Syst Pharm ,2005,62 (2) :173-181.
  • 5骆天红,郑以漫.胰升糖素样肽1对胰岛β细胞作用的研究进展[J].中华内分泌代谢杂志,2008,24(6). 被引量:38
  • 6Bunek MC, Diamant M, Comer A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine,in metformin-treated type 2 diabetes patients:a random- ized, controlled trail. Diabetes Care,2009,32 ( 5 ) :762-768.
  • 7董砚虎,付方明,高维国,李红,南海荣,孙滨,丁明,李利平,石海燕,马臻,王元善,王丽华.不同糖代谢状态人群胰岛素抵抗和胰岛β细胞功能研究[J].中华内分泌代谢杂志,2004,20(3):193-196. 被引量:30
  • 8陈蕾,贾伟平,项坤三.葡萄糖钳夹技术在糖尿病研究中的应用[J].中华内分泌代谢杂志,2003,19(1):74-76. 被引量:44
  • 9Klonoff DC, Buse JB, Nielsen LL, et al. Exenateffects on dia- betes, obesity, canliovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for 3 year. Curr Med Res Opin ,2008,24( 1 ) :275-286.
  • 10Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes : a randomized trial. Ann Inter Med,2005,143(8 ) :559-569.

二级参考文献85

  • 1Dov A, Abramovitch E, Warwar N, et al. Diminished phospho-diesterase-SB potentiates biphasic insulin response to glucose. Endocrinology, 2008,149:741-748.
  • 2Yaekura K, Julyan R, Wicksteed BL, et al. Insulin secretory deficiency and glucose intolerance in Rab3A null mice. J Biol Chem, 2003,278,9715-9721.
  • 3Doyte M, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev, 2003,55:105-131.
  • 4Park H, Dong X, Fisher TL, et al. Exendin-4 uses Irs 2 signaling to mediate pancreatic β cell growth and function. J Biol Chem, 2006, 281:1159-1168.
  • 5Knoch KP, Meisteffeld R, Kersting S, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells. Cell Metab, 2006,3:123-134.
  • 6Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes, 2006,55 : 1190-1196.
  • 7De Heer J, Hoist JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes, 2007,56:438-443.
  • 8MacDonald PE, Wheeler MB. Vohage-dependent K^+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia, 2003,46 : 1046-1062.
  • 9Dyachok O, Isakov Y, Sagetorp J, et al. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting β-cells. Nature, 2006,439 : 349- 352.
  • 10Kang G, Chepumy OG, Rindler MJ, et al. A cAMP and Ca^2+ coincidence detector in support of Ca^2+ -induced Ca^2+ release in mouse pancreatic β cells. J Physiol, 2005,566 : 173-188.

共引文献113

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部